Literature DB >> 6694682

Comparison of trends in the incidence of multiple myeloma in Malmö, Sweden, and other countries, 1950-1979.

I Turesson, O Zettervall, J Cuzick, J G Waldenstrom, R Velez.   

Abstract

Dramatic increases in mortality from multiple myeloma have been reported in the United States and the United Kingdom over the past three decades. To assess what fraction of this increase, if any, might be attributable to a change in the incidence of this disease, we examined the incidence of multiple myeloma during 1950 to 1979 in Malmö, Sweden, a city chosen because of its medical community's longstanding interest in this disease. The average annual incidence rates per 100,000 population were 4.9 for males and 3.7 for females (adjusted to the European age-standardized population). These rates are among the highest in the world. Unlike secular trends for myeloma in the United States and the United Kingdom, where large increases in mortality rates have been reported, the rates in Malmö have increased only slightly, and the increase was restricted to males, suggesting the possibility of environmental causes. We suggest that the rates in Malmö may represent the asymptote of myeloma's incidence that will be approached in other white populations as case ascertainment among them becomes complete.

Entities:  

Mesh:

Year:  1984        PMID: 6694682     DOI: 10.1056/NEJM198402163100703

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  12 in total

1.  Multiple myeloma.

Authors:  R M Meyer
Journal:  Can Fam Physician       Date:  1985-06       Impact factor: 3.275

Review 2.  Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations.

Authors:  F Wisløff; N Gulbrandsen; E Nord
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

3.  Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.

Authors:  E Nord; F Wisløff; M Hjorth; J Westin
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

4.  Monoclonal gammopathies in the west of Ireland: a preliminary study.

Authors:  J M Greally; G O'Toole; H McCann; H Grimes; B O'Connor; G Solan; N Walsh; E Egan
Journal:  Ir J Med Sci       Date:  1985-03       Impact factor: 1.568

5.  Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.

Authors:  Alexandre Decourt; Bertrand Gondouin; Jean Christophe Delaroziere; Philippe Brunet; Marion Sallée; Stephane Burtey; Bertrand Dussol; Vadim Ivanov; Regis Costello; Cecile Couchoud; Noemie Jourde-Chiche
Journal:  Clin J Am Soc Nephrol       Date:  2016-01-04       Impact factor: 8.237

6.  Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic.

Authors:  Ingemar Turesson; Ramon Velez; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

7.  The non-producer plasma cell myeloma. Report of a case and review of the literature.

Authors:  F Franchi; P Seminara; L Teodori; G Adone; P Bianco
Journal:  Blut       Date:  1986-05

8.  Socioeconomic status and risk of multiple myeloma.

Authors:  J M Johnston; S Grufferman; C C Bourguet; E Delzell; E R Delong; H J Cohen
Journal:  J Epidemiol Community Health       Date:  1985-06       Impact factor: 3.710

9.  Medical history and the risk of multiple myeloma.

Authors:  A Gramenzi; I Buttino; B D'Avanzo; E Negri; S Franceschi; C La Vecchia
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

10.  Trends in cancer incidence and mortality in Scotland: description and possible explanations.

Authors:  A J Swerdlow; I dos Santos Silva; A Reid; Z Qiao; D H Brewster; J Arrundale
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.